Estrogen replacement therapy and cardioprotection: Mechanisms and controversies

Brazilian Journal of Medical and Biological Research

Volumn 35, Issue 3, 2002, Pages 271-276

  Subbiah, M T R ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Estrogen receptors; Estrogen therapy; Lipoprotein oxidation; Nitric oxide synthesis; Plasma lipoproteins; Postmenopausal women; Thrombosis

Indexed keywords

ANTIOXIDANT; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN; PROTHROMBIN;

ANTIOXIDANT ACTIVITY; ARTERY; BLOOD VESSEL REACTIVITY; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; GENE MUTATION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROSTAGLANDIN SYNTHESIS; REVIEW; SIDE EFFECT; THROMBOGENICITY;

EID: 0036204257     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2002000300001     Document Type: Review

References (62)

1. Hormone replacement therapy, heart disease and other considerations
2. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of epidemiological evidence
3. Mechanisms of cardioprotection by estrogens
4. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women
5. Effects of estrogen replacement on the progression of coronary artery atherosclerosis
6. Commentary on the Women's Health Initiative
7. Design of the Women's Health Initiative clinical trial and observational study
8. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C)
9. Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: A cross-sectional study of 275 hyperlipidemic women
10. Hormone replacement therapy, prothrombotic mutations and the risk of incident non-fatal myocardial infarction in postmenopausal women
11. The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for the disease
12. A 12 week clinical trial determining the efficacy of synthetic conjugated estrogen A (SCE) in the treatment of vasomotor symptoms in African American and Caucasian postmenopausal women
13. How do we explain the clinical benefits of estrogen?
14. Hormone replacement therapy, hormone levels and lipoprotein cholesterol concentration in elderly women
15. Effects of postmenopausal hormone replacement therapy on lipoproteins including Lp(a) and LDL subfractions
16. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles: Comparison of transdermal and oral treatment regimens
17. Effects of conjugated estrogen with and without three different progestins on lipoproteins, high density lipoprotein sub-fractions and apolipoprotein A1
18. Subfractions of high density cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone
19. The lowering of lipoprotein (a) induced by estrogen plus progesterone therapy in postmenopausal women
20. Estradiol-17β as an antioxidant: Distinct features when compared to other fat soluble antioxidants
21. Antioxidant protection of LDL by physiological concentrations of 17β-estradiol. Requirement for estradiol modification
22. Superior and distinct antioxidant effect of selected estrogen metabolites on lipid peroxidation
23. Mechanisms involved in the protective effects of estradiol-17β on lipid peroxidation and DNA damage
24. 17β-Estradiol, progesterone and testosterone inversely modulate low density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages
25. Oestrogen and inhibition of oxidation of low density lipoproteins in post-menopausal women
26. Cardio-protective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and LDL oxidation in postmenopausal women
27. Effects of antiestrogen tamoxifen and conjugated estrogens on low density lipoprotein concentration and oxidation in postmenopausal women
28. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women
29. Acute effect of 17 beta estradiol on rabbit coronary artery contractile response to endothelin-1
30. Short term administration of estrogens and vascular response of atherosclerotic coronary arteries
31. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor response to acetylcholine in postmenopausal women
32. Beneficial effect of estrogen on exercise induced myocardial ischemia in women with coronary artery disease
33. 17β-Estradiol attenuates acetyl choline induced coronary arterial constriction in women but not men with coronary heart disease
34. Nitric oxide accounts for dose dependent estrogen mediated coronary relaxations after acute estrogen withdrawal
35. Effects of short term transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women
36. Upregulation of nitric oxide synthase by estradiol in human endothelial cells
37. Castration increases and androgens decrease nitric oxide synthase activity in the brain: Physiological implications
38. Estrogen receptor α mediates the non-genomic activation of endothelial nitric oxide synthase by estrogen
39. The protective effects of estrogen on the cardiovascular system
40. Experimental atherosclerosis: Effect of estrogen and atherosclerosis on thromboxane and prostacyclin formation
41. Estrogen reduces proliferation and agonist induced calcium increase in coronary artery smooth muscle cells
42. Association of hormone replacement therapy with hemostatic and other cardio-vascular risk factors
43. Effect of hormone replacement therapy on fibrinolysis in postmenopausal women
44. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
45. Effects of estradiol on cytokine-induced endothelial cell adhesion molecule expression
46. Androgen exposure increase human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule
47. The vascular protective effect of estrogen
48. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha
49. Human estrogen receptor beta: Gene structure, chromosomal localization and expression pattern
50. Comparison of the ligand binding specificities and transcript tissue distribution of estrogen receptors α and β
51. Effect of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice
52. Mechanisms of estrogen action
53. Endocrine and paracrine hormones in the promotion, progression and reoccurrence of breast cancer
54. Estrogen, DNA damage and mutations
55. Postmenopausal estrogen and breast cancer
56. Biological and endocrinological insights into the possible breast cancer risk from menopausal estrogen replacement therapy
57. Selective estrogen receptor modulators: An alternative to estrogen replacement therapy
58. Association of estrogens with human plasma lipoproteins: Studies using estradiol-17β and its hydrophobic derivative
59. A comparison of the esterification of steroids by rat lecithin: Cholesterol acyl transferase and acyl coenzyme A:cholesterol transferase
60. Transfer of dehydroepiandrosterone and pregnenolone-fatty acid esters between human lipoproteins
61. Potential role of HDL in the manifestation of anti-oxidant effect of estrogens on LDL peroxidation
62. Uptake and protection against oxidative stress by estrogen esters in THP-1 human macrophage cell lines